Inquiry Basket
Loading ......
Filter By Product Search for
CCL22
CCL22 Full Name
chemokine (C-C motif) ligand 22
CCL22 Introduction
CCL22, also known as macrophage-derived chemokine (MDC), has emerged as a highly relevant immune signaling molecule in inflammation, cancer biology, neuroimmune communication, and infectious disease research. As one of the principal ligands for the CCR4 receptor, CCL22 plays a central role in directing immune cell trafficking, especially the migration of regulatory T cells (Tregs), Th2 lymphocytes, monocytes, and natural killer cells. Researchers have become increasingly interested in the CCL22–CCR4 signaling axis because abnormal immune-cell recruitment is a common challenge across many chronic diseases, including cancer, autoimmune disorders, fibrosis, and neuroinflammatory conditions. Recent studies further demonstrate that CCL22 is not simply a passive chemokine but a dynamic immune regulator capable of reshaping local tissue immunity, peripheral sensitization, and inflammatory balance. Its highly selective receptor interactions and distinct receptor-desensitization properties compared with CCL17 have also made CCL22 an attractive molecular target for next-generation immunotherapies and precision medicine strategies.
One of the most important biological functions of CCL22 is its ability to coordinate immune tolerance and inflammatory control under both physiological and pathological conditions. Under healthy conditions, CCL22 contributes to thymic T-cell maturation and helps maintain immune homeostasis by balancing effector T cells and immunosuppressive Treg populations. However, dysregulated CCL22 expression can significantly alter immune responses and tissue behavior. Recent neuroimmunology research has revealed that dendritic cell-derived CCL22 can directly activate CCR4-positive sensory neurons after tissue injury, increasing neuronal excitability and contributing to peripheral sensitization and chronic pain signaling. Elevated CCL22 levels have also been detected in traumatic brain injury, ischemic stroke, fibromyalgia, neonatal hypoxic-ischemic brain injury, and other central nervous system disorders, highlighting its expanding role in neuroinflammation and tissue remodeling. At the same time, CCL22 may exert anti-inflammatory effects through promoting M2 microglial polarization in certain disease contexts, illustrating its complex dual role as both a protective and pathogenic mediator depending on the surrounding immune environment.
CCL22 has become particularly important in oncology and infectious disease research because of its strong association with immune suppression and disease progression. In many tumors, elevated CCL22 expression recruits CCR4-positive Treg cells into the tumor microenvironment, creating an immunosuppressive niche that allows malignant cells to evade immune surveillance and resist anti-tumor immunity. This mechanism has been observed across multiple cancers and is now considered a major obstacle in effective cancer immunotherapy, making the CCL22–CCR4 axis a promising therapeutic target. In infectious diseases such as COVID-19, recent evidence suggests that SARS-CoV-2 infection may suppress or neutralize CCL22 activity, disrupting thymic T-cell maturation and contributing to lymphopenia, cytokine dysregulation, and severe inflammatory responses. These findings have increased interest in CCL22 not only as a biomarker for immune dysfunction and disease severity but also as a potential therapeutic entry point for controlling pathological inflammation while preserving immune balance. As translational research advances, CCL22 is increasingly viewed as a multifunctional immunological target with broad relevance to cancer therapy, neuroimmune disease management, antiviral strategies, and precision immunomodulation.
Alternate Names for CCL22
CCL22; chemokine (C-C motif) ligand 22; MDC; ABCD-1; SCYA22; STCP-1; DC/B-CK; A-152E5.1; C-C motif chemokine 22; MDC(1-69)
Loading ......
